FINWIRES · TerminalLIVE
FINWIRES

Sector Update: Healthcare Stocks Softer Monday Afternoon

By

Healthcare stocks declined Monday afternoon with the NYSE Healthcare Index dropping 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.

The iShares Biotechnology ETF (IBB) rose 0.5%.

In sector news, the Centers for Medicare & Medicaid Services proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price-applicability year, shifting to codified regulations from implementation through annual guidance.

In corporate news, Neumora Therapeutics (NMRA) shares tumbled 52% after the company halted development of its major depressive disorder treatment navacaprant after two Phase 3 trials failed to meet their primary and key secondary endpoints. Neumora also announced it will reduce its workforce by 35%.

Elicio Therapeutics (ELTX) shares plunged 72% after the company said a Phase 2 study assessing the experimental pancreatic cancer therapy ELI-002 7p did not meet the prespecified primary endpoint of disease-free survival.

Cuprina Holdings (CUPR) shares more than doubled after a subsidiary obtained 510(k) clearance from the US Food and Drug Administration for its Medifly Maggots product that uses Lucilia cuprina larvae in maggot debridement therapy.

Related Articles

Sectors

Sector Update: Energy Stocks Higher Late Afternoon

Energy stocks rose late Friday afternoon, with the NYSE Energy Sector Index increasing 0.6% and the State Street Energy Select Sector SPDR ETF (XLE) adding 0.7%.The Philadelphia Oil Service Sector Index shed 0.1%, and the Dow Jones US Utilities Index rose 0.9%.Oil prices fell following media reports that the US and Iran are nearing a potential peace deal, just days after the two sides exchanged strikes in a sharp escalation of tensions since a ceasefire in April.US Energy Secretary Chris Wright said about 7 million barrels of daily oil and fuel shipments are flowing through the Strait of Hormuz, or about half the volumes stranded at the start of the war with Iran, Bloomberg reported.West Texas Intermediate crude oil fell 3.7% to $84.51 a barrel, and global benchmark Brent dropped 3.8% to $86.99 a barrel. Henry Hub natural gas futures rose 1.3% to $3.13 per 1 million BTU.In corporate news, Exxon Mobil (XOM) is studying potential takeover targets, including Woodside Energy (WDS), as the energy giant looks to increase its presence in the liquefied natural gas sector and in Asian markets, Bloomberg reported. Exxon shares rose 0.2%, and Woodside jumped past 6%.Shell (SHEL) said Friday it has suspended its ongoing $3 billion share buyback program. The suspension, effective Friday through July 14, is related to securities law requirements following publication of the shareholder circular by ARC Resources, Shell said. Separately, Shell is planning to begin the sale of its offshore wind farms for over $1 billion by the end of this year as the company prioritizes its fossil fuel business, Bloomberg reported. Shell shares were 0.4% lower.BP (BP) started a process to sell minority stakes in its Kaskida and Tiber projects in the Gulf of Mexico, Reuters reported. BP shares were fractionally higher.Venture Global (VG) shares were rising 2%. The company and Greece-based Atlantic-SEE LNG Trade said late Thursday they expanded their existing sales and purchase agreement for US liquefied natural gas. Venture Global also said late Thursday it closed an offering of $1.13 billion of 6.375% senior secured notes due Dec. 15, 2034, and $1.13 billion of 6.625% senior secured notes due June 15, 2036.

$BP$SHEL$VG$WDS$XOM
Sectors

Sector Update: Consumer Stocks Mixed Late Afternoon

Consumer stocks were mixed late Friday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 0.5% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) decreasing 0.1%.US consumer sentiment has rebounded in June as gasoline prices eased, while the inflation outlook dropped, the University of Michigan's preliminary survey showed Friday. The main sentiment index rose 9.2% sequentially to 48.9 this month, following three consecutive drops. The consensus was for a 46 print in a Bloomberg poll.In corporate news, Target (TGT) is showing early signs of a potential multiyear turnaround after a strong start to 2026, with UBS Securities saying the retailer's transformation has multiple stages beyond the initial comp recovery. UBS has a buy rating on the stock and a price target of $144. Target shares climbed 2.1%.Lennar (LEN) shares fell 4.3% after the homebuilder issued a fiscal Q3 delivery outlook below market estimates, while its revenue trailed expectations in the previous three-month period amid persistent housing market headwinds.Uber (UBER) is contacting parties interested in Delivery Hero's regional businesses as it seeks regulatory approval for its planned takeover of the German food delivery company, Bloomberg reported. Uber shares were down 1.5%.Pilgrim's Pride (PPC) shares added 1.5% after it said Friday it is investing $75 million to expand and overhaul its poultry facility in Ellijay, Georgia.

$LEN$PPC$TGT$UBER
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 1%.AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer. AstraZeneca shares were declining 1.6%.Jazz Pharmaceuticals (JAZZ) shares fell 1.2% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped past 7%.

$AVTX$AZN$JAZZ$MRK